CMR Quantification of Myocardial Scar Provides Additive Prognostic Information in Nonischemic Cardiomyopathy

Overview

Journal JACC Cardiovasc Imaging

Publisher Elsevier

Specialties Cardiology & Vascular Diseases
Radiology

Date 2013 Aug 13

PMID 23932642

Citations 88

Authors

Tomas G Neilan

Otavio R Coelho-Filho

Stephan B Danik

Ravi V Shah

John A Dodson

Daniel J Verdini

Michifumi Tokuda

Caroline A Daly

Usha B Tedrow

William G Stevenson

Michael Jerosch-Herold

Brian B Ghoshhajra

Raymond Y Kwong

Affiliations

Soon will be listed here.

Abstract

Objectives: This study sought to determine whether the extent of late gadolinium enhancement (LGE) can provide additive prognostic information in patients with a nonischemic dilated cardiomyopathy (NIDC) with an indication for implantable cardioverter-defibrillator (ICD) therapy for the primary prevention of sudden cardiac death (SCD).

Background: Data suggest that the presence of LGE is a strong discriminator of events in patients with NIDC. Limited data exist on the role of LGE quantification.

Methods: The extent of LGE and clinical follow-up were assessed in 162 patients with NIDC prior to ICD insertion for primary prevention of SCD. LGE extent was quantified using both the standard deviation-based (2-SD) method and the full-width half-maximum (FWHM) method.

Results: We studied 162 patients with NIDC (65% male; mean age: 55 years; left ventricular ejection fraction [LVEF]: 26 ± 8%) and followed up for major adverse cardiac events (MACE), including cardiovascular death and appropriate ICD therapy, for a mean of 29 ± 18 months. Annual MACE rates were substantially higher in patients with LGE (24%) than in those without LGE (2%). By univariate association, the presence and the extent of LGE demonstrated the strongest associations with MACE (LGE presence, hazard ratio [HR]: 14.5 [95% confidence interval (CI): 6.1 to 32.6; p < 0.001]; LGE extent, HR: 1.15 per 1% increase in volume of LGE [95% CI: 1.12 to 1.18; p < 0.0001]). Multivariate analyses showed that LGE extent was the strongest predictor in the best overall model for MACE, and a 7-fold hazard was observed per 10% LGE extent after adjustments for patient age, sex, and LVEF (adjusted HR: 7.61; p < 0.0001). LGE quantitation by 2-SD and FWHM both demonstrated robust prognostic association, with the highest MACE rate observed in patients with LGE involving >6.1% of LV myocardium.

Conclusions: LGE extent may provide further risk stratification in patients with NIDC with a current indication for ICD implantation for the primary prevention of SCD. Strategic guidance on ICD therapy by cardiac magnetic resonance in patients with NIDC warrants further study.

Citing Articles

Utilization of Cardiac Magnetic Resonance Imaging for Assessing Myocardial Fibrosis in Prognosis Evaluation and Risk Stratification of Patients with Dilated Cardiomyopathy.

Feng X, Zheng Y, Yang Y, He W, Yang F, Wang L Rev Cardiovasc Med. 2025; 26(1):25654.

PMID: 39867184 PMC: 11759975. DOI: 10.31083/RCM25654.

Magnetization-transfer flow-independent dark-blood delayed enhancement cardiac MRI optimizes discrimination of ST-elevation myocardial infarct borders.

Poskaite P, Kremser C, Pamminger M, Troger F, Reiter G, Reinstadler S Eur Radiol. 2024; .

PMID: 39636422 DOI: 10.1007/s00330-024-11192-7.

Quantification of Replacement Fibrosis in Aortic Stenosis: A Narrative Review on the Utility of Cardiovascular Magnetic Resonance Imaging.

Rajah M, Doubell A, Herbst P Diagnostics (Basel). 2024; 14(21).

PMID: 39518402 PMC: 11544846. DOI: 10.3390/diagnostics14212435.

Risk Stratification in Nonischemic Dilated Cardiomyopathy Using CMR Imaging: A Systematic Review and Meta-Analysis.

Eichhorn C, Koeckerling D, Reddy R, Ardissino M, Rogowski M, Coles B JAMA. 2024; .

PMID: 39298146 PMC: 11413760. DOI: 10.1001/jama.2024.13946.

Optimizing ventricular tachycardia ablation through imaging-based assessment of arrhythmic substrate: A comprehensive review and roadmap for the future.

Burger J, Hopman L, Kemme M, Hoeksema W, Takx R, Figueras I Ventura R Heart Rhythm O2. 2024; 5(8):561-572.

PMID: 39263615 PMC: 11385403. DOI: 10.1016/j.hroo.2024.07.001.

References

Salerno-Uriarte J, De Ferrari G, Klersy C, Pedretti R, Tritto M, Sallusti L . Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. J Am Coll Cardiol. 2007; 50(19):1896-904. DOI: 10.1016/j.jacc.2007.09.004. View

Desai A, Fang J, Maisel W, Baughman K . Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004; 292(23):2874-9. DOI: 10.1001/jama.292.23.2874. View

Bogun F, Desjardins B, Good E, Gupta S, Crawford T, Oral H . Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009; 53(13):1138-45. PMC: 2747602. DOI: 10.1016/j.jacc.2008.11.052. View

Maisel W, Moynahan M, Zuckerman B, Gross T, Tovar O, Tillman D . Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA. 2006; 295(16):1901-6. DOI: 10.1001/jama.295.16.1901. View

Iles L, Pfluger H, Lefkovits L, Butler M, Kistler P, Kaye D . Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011; 57(7):821-8. DOI: 10.1016/j.jacc.2010.06.062. View

Flett A, Hayward M, Ashworth M, Hansen M, Taylor A, Elliott P . Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010; 122(2):138-44. DOI: 10.1161/CIRCULATIONAHA.109.930636. View

Wu K, Weiss R, Thiemann D, Kitagawa K, Schmidt A, Dalal D . Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008; 51(25):2414-21. PMC: 2459322. DOI: 10.1016/j.jacc.2008.03.018. View

Nazarian S, Bluemke D, Lardo A, Zviman M, Watkins S, Dickfeld T . Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005; 112(18):2821-5. PMC: 2943964. DOI: 10.1161/CIRCULATIONAHA.105.549659. View

Kadish A, Dyer A, Daubert J, Quigg R, Mark Estes N, Anderson K . Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004; 350(21):2151-8. DOI: 10.1056/NEJMoa033088. View

10.

Dec G, Fuster V . Idiopathic dilated cardiomyopathy. N Engl J Med. 1994; 331(23):1564-75. DOI: 10.1056/NEJM199412083312307. View

11.

Goldberger J, Cain M, Hohnloser S, Kadish A, Knight B, Lauer M . American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the.... Circulation. 2008; 118(14):1497-1518. View

12.

Vrtovec B, Delgado R, Zewail A, Thomas C, Richartz B, Radovancevic B . Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation. 2003; 107(13):1764-9. DOI: 10.1161/01.CIR.0000057980.84624.95. View

13.

Tung R, Zimetbaum P, Josephson M . A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol. 2008; 52(14):1111-21. DOI: 10.1016/j.jacc.2008.05.058. View

14.

Liebson P, Grandits G, Prineas R, Dianzumba S, Flack J, Cutler J . Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993; 87(2):476-86. DOI: 10.1161/01.cir.87.2.476. View

15.

Richardson P, McKenna W, Bristow M, Maisch B, MAUTNER B, OConnell J . Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996; 93(5):841-2. DOI: 10.1161/01.cir.93.5.841. View

16.

Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S . Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009; 169(16):1500-6. DOI: 10.1001/archinternmed.2009.255. View

17.

Broberg C, Chugh S, Conklin C, Sahn D, Jerosch-Herold M . Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ Cardiovasc Imaging. 2010; 3(6):727-34. PMC: 3048790. DOI: 10.1161/CIRCIMAGING.108.842096. View

18.

Kim R, Fieno D, Parrish T, Harris K, Chen E, Simonetti O . Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999; 100(19):1992-2002. DOI: 10.1161/01.cir.100.19.1992. View

19.

Flett A, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C . Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011; 4(2):150-6. DOI: 10.1016/j.jcmg.2010.11.015. View

20.

Jacobson A, Senior R, Cerqueira M, Wong N, Thomas G, Lopez V . Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55(20):2212-21. DOI: 10.1016/j.jacc.2010.01.014. View